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Pharmacomodulation
 The hunt for the pharmacophore
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Context 1-3
 Malaria is a vector-borne parasitosis, responsible of 435 000 deaths and 219
million of cases in 2017.
 Disease mainly caused by Plasmodium falciparum for which a resistance
phenomenon to artemisinin is documented.
 Considering this resistance and the prevalence of malaria, development of new
antiplasmodials represents an urgent need.
 Ellagic acid (EA, 1) seems to be one of the most promising candidates: 105-330 nM
in vitro and no toxic.
 Poor oral bioavailability due to a reduced water solubility (9.7 µg/mL).
Objectives
1. Synthesis of steric-hindered EA analogues or EA prodrugs using phenolic 
positions.
Direct synthesis approach vs total synthesis strategy
2. Evaluation of antiplasmodial effect against 3D7 strain (chloroquine-
sensitive)4
3. Measuring impact of pharmacomodulations on water solubility thanks to 
UV-spectrophotometer.





1 / H H 13.24±8.37 (2) 267.72±21.52
2
H H H 125.19±5.76 (3) 9658.79±983.38
3
CH3 H H 90.87±17.52 (3) 11654.95±2560.76
4
CH3 CH3CO CH3CO 44.27±13.75 (3) 957.52±151.72
5
CH3 BnCH2 CH3CO 33.27±12.86 (3) 14.70±3.20
6
CH3 BnCH2 H 54.11±13.02 (3) 163.21±9.22
7
CH3 BnCH2 MOM 43.83 (1) Liq.
8
H BnCH2 MOM 58.74±28.25 (3) wip
9
CH2CH3CH2OPMB BnCH2 MOM 19.89±4.16 (4) liq.
10
CH2CH3CH2OH BnCH2 MOM 85.29±12.42 (3) liq.
11
CH2CH3CH2 BnCH2 MOM 13.93±6.75 (3) wip
12
CH2CH3CH2 BnCH2 H 3.59±0.14 (4) wip
13
CH2CH3CH2 BnCH2 H wip wip
14
/ BnCH2 H wip wip
Conclusion & Prospects
 Increase of inhibitory effect from gallic acid (2) (125.2 µM), especially when 
a linker is present between 2 gallate moieties. “Dimer look-alike” 
importance to observe the same rank of potency of EA.
 Substituents on the phenolic functions negatively impact this effect (11 vs 
12). 
 Solubility seems to be mainly dependent of phenolic functions. 
 In the near future: Assay of final substituted compound and synthesis of 
other derivatives of EA’s scaffold.
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Synthesis
i CH3OH, H2SO4 ii Ac2O, H2SO4 iii BnBr, KI, K2CO3, acetone iv K2CO3 , CH3OH, H2O v NaH, MOMCl, DMF vi LiOH, CH3OH, THF, H2O vii 
1,3-propanediol-PMB, DMAP, EDCI-HCl, CH2Cl2 viii DDQ, Sorenson’s buffer, CH2Cl2 ix DMAP, EDCI-HCl, CH2Cl2 x THF, IPA/HCl xi 
CuCL2 , n-BuNH2, CH3OH xii LiOH, CH3OH, THF, H2O 
wip = Work In Progress; Liq. = liquid
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